Hydroxychloroquine in systemic lupus erythematosus

Lancet

Volumn 369, Issue 9569, 2007, Pages 1257-1258

  Costedoat Chalumeau, Nathalie ^a   Amoura, Zahir ^a   Hulot, Jean Sébastien ^a   Lechat, Philippe ^a   Piette, Jean Charles ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE;

HUMAN; LETTER; MEDICAL RESEARCH; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT PLANNING;

EID: 34047271465     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60591-1     Document Type: Letter

References (5)

1. D'Cruz D., Khamashta M., and Hughes G. Systemic lupus erythematosus. Lancet 369 (2007) 587-596
2. Kasitanon N., Fine D., Haas M., Magder L., and Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 15 (2006) 366-370
3. Fessler B., Alarcon G., McGwin Jr. G., et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 52 (2005) 1473-1480
4. Costedoat-Chalumeau N., Amoura Z., Hulot J., et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 54 (2006) 3284-3290
5. Petri M., Kim M., Kalunian K., et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353 (2005) 2550-2558